Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to improve access to hepatitis C treatment and cure options for Americans.
The problem
Hepatitis C is a serious liver disease affecting millions. Some people lack access to expensive treatments or don't know they have the disease.
The proposal
The bill likely expands hepatitis C screening, treatment access, and funding. Specifics unavailable as no official summary was released yet.
The impact
Patients with hepatitis C, healthcare providers, and insurance companies would be affected by increased screening and treatment availability.
Modern hepatitis C treatments cure the disease in most patients. Better access means more people can get treatment and be cured instead of living with the disease long-term.
Untreated hepatitis C can cause liver damage, cirrhosis, and cancer. Catching and treating it early prevents severe complications and deaths.
Treating hepatitis C early costs less than treating advanced liver disease later. Upfront treatment spending saves money on emergency care and liver transplants.
Many people don't know they have hepatitis C. Better screening finds cases early when treatment works best and stops disease spread.
Hepatitis C treatments are expensive, sometimes costing thousands per patient. Expanding access requires significant government or insurance spending initially.
Without knowing the bill's details, the cost to taxpayers is unclear. Federal funding means public money goes to this program instead of other priorities.
Rolling out screening and treatment nationwide takes time and coordination. Healthcare systems may struggle with sudden increased demand for services.
The bill might require states or healthcare providers to spend money without providing funding. This could strain local budgets and healthcare systems.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.